Table 1 Correlation between VPS35 levels in GC patients and their clinicopathological characteristics.
Clinicopathological features | Number | Low expression N (%) | High expression N (%) | p value |
|---|---|---|---|---|
Age | ||||
 <60 | 35 | 11 (31.4) | 24 (68.6) | 0.857 |
 ≥60 | 54 | 16 (29.6) | 38 (70.4) |  |
Gender | ||||
 Male | 61 | 19 (31.1) | 42 (68.9) | 0.806 |
 Female | 28 | 8 (28.6) | 20 (71.4) |  |
Tumour size | ||||
 ≤5 cm | 46 | 21 (45.7) | 25 (54.3) | 0.001** |
 >5 cm | 43 | 6 (14.0) | 37 (86.0) |  |
T stage | ||||
 I– II | 14 | 9 (64.3) | 5 (35.7) | 0.003** |
 III– IV | 75 | 18 (24.0) | 57 (76.0) |  |
N stage | ||||
 0–I | 37 | 16 (43.2) | 21 (56.8) | 0.025* |
 II–III | 52 | 11 (21.2) | 41 (78.8) |  |
Vascular invasion | ||||
 Negative | 65 | 24 (36.9) | 41 (63.1) | 0.026* |
 Positive | 24 | 3 (12.5) | 21 (87.5) |  |
AJCC | ||||
 I–II | 34 | 15 (44.1) | 19 (55.9) | 0.026* |
 III–IV | 55 | 12 (21.8) | 43 (78.2) |  |
